WO2006037922A1 - Composition cosmetique et/ou dermatologique pour peaux sensibles - Google Patents
Composition cosmetique et/ou dermatologique pour peaux sensibles Download PDFInfo
- Publication number
- WO2006037922A1 WO2006037922A1 PCT/FR2005/050807 FR2005050807W WO2006037922A1 WO 2006037922 A1 WO2006037922 A1 WO 2006037922A1 FR 2005050807 W FR2005050807 W FR 2005050807W WO 2006037922 A1 WO2006037922 A1 WO 2006037922A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactobacillus
- metabolites
- fractions
- bifidobacterium
- microorganism
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 107
- 230000037307 sensitive skin Effects 0.000 title claims description 43
- 239000002537 cosmetic Substances 0.000 title claims description 22
- 244000005700 microbiome Species 0.000 claims abstract description 108
- 239000002207 metabolite Substances 0.000 claims abstract description 54
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 35
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 32
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 30
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 12
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 48
- 230000037336 dry skin Effects 0.000 claims description 33
- 206010013786 Dry skin Diseases 0.000 claims description 28
- 241000186660 Lactobacillus Species 0.000 claims description 24
- 150000001768 cations Chemical class 0.000 claims description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 18
- 239000011707 mineral Substances 0.000 claims description 18
- 229940039696 lactobacillus Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- -1 oxides Chemical class 0.000 claims description 12
- 239000006041 probiotic Substances 0.000 claims description 12
- 235000018291 probiotics Nutrition 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 4
- 241000235070 Saccharomyces Species 0.000 claims description 4
- 241000235006 Torulaspora Species 0.000 claims description 4
- 241000235013 Yarrowia Species 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 241000235349 Ascomycota Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 241000193798 Aerococcus Species 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000605909 Fusobacterium Species 0.000 claims description 2
- 241000235649 Kluyveromyces Species 0.000 claims description 2
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 241000186715 Lactobacillus alimentarius Species 0.000 claims description 2
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 2
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 2
- 241000186612 Lactobacillus sakei Species 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000192132 Leuconostoc Species 0.000 claims description 2
- 241001468189 Melissococcus Species 0.000 claims description 2
- 241000192041 Micrococcus Species 0.000 claims description 2
- 241000202223 Oenococcus Species 0.000 claims description 2
- 241000192001 Pediococcus Species 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000191973 Staphylococcus xylosus Species 0.000 claims description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 241000202221 Weissella Species 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052790 beryllium Inorganic materials 0.000 claims description 2
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000001805 chlorine compounds Chemical class 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 150000002315 glycerophosphates Chemical class 0.000 claims description 2
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 150000003893 lactate salts Chemical class 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 150000004701 malic acid derivatives Chemical class 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 150000003892 tartrate salts Chemical class 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000194035 Lactococcus lactis Species 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 claims 1
- 241000186605 Lactobacillus paracasei Species 0.000 abstract description 26
- 244000199866 Lactobacillus casei Species 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 31
- 239000000843 powder Substances 0.000 description 27
- 235000013336 milk Nutrition 0.000 description 16
- 210000004080 milk Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000006210 lotion Substances 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 235000010755 mineral Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 239000008298 dragée Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 6
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 101100311260 Caenorhabditis elegans sti-1 gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000037189 immune system physiology Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000001755 magnesium gluconate Substances 0.000 description 3
- 235000015778 magnesium gluconate Nutrition 0.000 description 3
- 229960003035 magnesium gluconate Drugs 0.000 description 3
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010021197 Ichthyoses Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000010473 blackcurrant seed oil Substances 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011868 grain product Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940074358 magnesium ascorbate Drugs 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- XXBAQTDVRLRXEV-UHFFFAOYSA-N 3-tetradecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCOCCCO XXBAQTDVRLRXEV-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000287513 Anhingidae Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical class CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940116987 ppg-3 myristyl ether Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 229940026236 strontium nitrate Drugs 0.000 description 1
- QRVYVKGHSWMAJI-IYEMJOQQSA-L strontium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Sr+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O QRVYVKGHSWMAJI-IYEMJOQQSA-L 0.000 description 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Definitions
- the present invention relates primarily to the use of a combination of specific microorganisms for the preparation of a composition, in particular a cosmetic and / or dermatological composition intended more particularly for the prevention and / or the treatment. skins qualified as sensitive and / or dry skin. It also relates to corresponding compositions.
- sensitive skin is defined by a particular reactivity of the skin.
- this reactivity is not an immunological process that is to say does not occur only in a skin already sensitized, in response to the presence of a allergen. Its mechanism is said to be nonspecific.
- This cutaneous reactivity generally results in the appearance of signs of discomfort in response to the contacting of the subject with a triggering element that may have various origins. It can be the application of a cosmetic product on the surface of sensitive skin, food intake, exposure to sudden changes in temperature, air pollution and / or radiation rays. ultraviolet or infrared. There are also associated factors like age and skin type. Sensitive skin is therefore more common among dry or oily skin than normal skin. The appearance of these signs of discomfort, which appear in the minutes following the contact of the subject with the triggering element, is one of the essential characteristics of sensitive skin. It is mostly dysesthetic sensations.
- dysaesthetic sensations we mean more or less painful sensations felt in a cutaneous zone, such as tingling, tingling, itching or pruritus, burning, heating, discomfort, tightness, etc.
- These subjective signs most often exist in the absence of visible chemical signs such as redness and flaking.
- these skin irritation and intolerance reactions are notably related to a release of neuropeptides by the nerve endings of the epidermis and the dermis.
- this problem is particularly exacerbated in the case where this sensitive skin is associated to dry skin. Dry skin is primarily characterized by tightness and / or tension and is often associated with decreased cutaneous hydration and impaired barrier function as measured by insensitive water loss.
- WO 02/28402 discloses that probiotic microorganisms may have a beneficial effect in the regulation of cutaneous hypersensitivity reactions such as inflammatory and allergic reactions that are the result of an immunological process as opposed to the reactivity of sensitive skin. It is also milk condition in "Probiotics in the Managment of Atopic Eczema, Clinical and Experimental Allergy 2000", Volume 30, pages 1604-1610, a study reporting the individual effect of some probiotics on infantile immune mechanisms such as dermatitis atopic.
- the inventors have found that a combination of at least two specific probiotic microorganisms proved to be particularly effective, particularly in adults, for the treatment of sensitive skin, especially associated with dry skin.
- the combination of microorganisms, considered according to the invention advantageously exhibits a potential activity at the level of the cutaneous barrier and a particular valence in the maintenance of the defense mechanisms thus favoring the maintenance of cutaneous homeostasis and the regulation of the immune system. the skin.
- the present invention relates, according to a first aspect, the use of an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , one of their fractions or one of their metabolites in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, one of their fractions or one of their metabolites for the preparation of a composition useful for preventing and / or treating sensitive and / or dry skin.
- the present invention further relates in another of its aspects, a cosmetic treatment method for preventing and / or treating sensitive and / or dry skin, comprising the administration, in particular oral or topical, of an effective amount.
- a cosmetic treatment method for preventing and / or treating sensitive and / or dry skin comprising the administration, in particular oral or topical, of an effective amount. of at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , one of their fractions or one of their metabolites in combination with a quantity effective of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, one of their fractions or one of their metabolites.
- this combination is formulated in the form of a composition for oral absorption. It can especially be a food supplement or a foodstuff.
- the present invention also relates, according to another of its aspects, to a cosmetic and / or dermatological composition, in particular useful for preventing and / or treating sensitive and / or dry skin, comprising in a physiologically acceptable support an effective amount of at least a microorganism belonging to the species Lactobacillus paracasei STI 1 NCC 2461 (CNCM 1-2116), one of its fractions or one of its metabolites in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, one of their fractions or one of their metabolites.
- the present invention relates, in another of its aspects, to a cosmetic and / or dermatological composition, in particular useful for preventing and / or treating sensitive and / or dry skin, comprising in a physiologically acceptable carrier an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , one of their fractions or one of their metabolites, in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, the one of their fractions or one of their metabolites and further comprising at least one divalent cation.
- the present invention relates to a cosmetic and / or dermatological composition, in particular useful for preventing and / or treating sensitive and / or dry skin, comprising in a physiologically acceptable carrier an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , one of their fractions or one of their metabolites, in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium Longum NCC 490 (CNCM 1- 2170) or Bifidobacterium lactis NCC 2818 (CNCM 1-3446), one of their fractions or one of their metabolites.
- a cosmetic and / or dermatological composition in particular useful for preventing and / or treating sensitive and / or dry skin, comprising in a physiologically acceptable carrier an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , one of their fractions or one of their metabolites, in combination with an effective amount of at least one microorganism belonging
- the present invention also relates, according to another of its aspects, to a composition for oral absorption, particularly of the dietary supplement type, comprising in a physiologically acceptable carrier an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei STl 1 NCC 2461, (CNCM 1-2116), one of its fractions or one of its metabolites in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, one of their fractions or one of their metabolites.
- the present invention relates to a composition for oral absorption, in particular of the dietary supplement type, comprising in a physiologically acceptable support an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or caseol, one of their fractions or one of their metabolites, in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, one of their fractions or one of their metabolites and further comprising at least one divalent cation.
- a composition for oral absorption in particular of the dietary supplement type, comprises, in a physiologically acceptable support, an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or casei, one of their fractions or one of their metabolites in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum NCC 490 (CNCM 1-2170) or Bifidobacterium lactis NCC 2818 (CNCM 1-3446 ), one of their fractions or one of their metabolites.
- Bifidobacterium longum NCC 490 CNCM 1-2170
- Bifidobacterium lactis NCC 2818 CNCM 1-3446
- Sensitive and / or dry skin As previously mentioned, sensitive skin is different from allergic skin. Its reactivity is not an immunological process and usually results only in dysesthetic sensations.
- Thallers Subjects reporting moderate or severe tingling sensations are referred to as "stingers" and are considered to be sensitive skin. Because of this cutaneous sensitivity to the topical application of product, these subjects are then selected to test products known as sensitive skin. More recently, to specifically activate the peripheral nerve endings, involved in the discomfort and called nociceptors, recently identified as being involved in sensitive skin, new tests have been proposed that use precisely other discomfort inducers such as capsaicin. This second type of test, described in application EP 1 374 913, is also another tool that is particularly useful for the diagnosis of sensitive skin.
- sensitive skin covers irritable skin and intolerant skin.
- An intolerant skin is a skin that reacts with sensations of heating, tugging, tingling and / or redness, to various factors such as the application of cosmetic or dermatological products or soap. In general, these signs are associated with erythema and hyper-seborrhoeic or acneic skin, or even rosacea, with or without darter.
- Irritable skin is a skin that reacts with pruritus, that is to say itching or tingling, to various factors such as the environment, emotions, food, wind, friction, razor , hard water with a high concentration of limestone, temperature variations or wool.
- these two types of skin may be associated with dry skin with or without scale or skin that has erythema.
- skin dryness is often associated with a decrease in skin hydration rate, assessed by corneometry and an alteration of the barrier function, measured by the insensitive loss of water. Dry skin is essentially a feeling of tightness and / or tension. It is also rough to the touch and appears covered with scales.
- the origin of this dry skin can be constitutional or acquired.
- constitutional dry skin two categories can be distinguished: pathological skin and non-pathological skin.
- the constitutional dry pathological skins are essentially represented by atopic dermatitis and ichthyoses. They are almost independent of external conditions.
- Atopic dermatitis is described as associated with a deficit in the lipid metabolism of the stratum corneum and in particular ceramides. This pathology is in the form of more or less chronic xerosis over a large area of the body, associated with inflammatory and pruriginous plaques.
- Ichthyoses are pathologies characterized by a genetic deficit affecting the process of keratinization at different stages. They are manifested by a large plaque desquamation.
- the non-pathological constitutional dry skin is dry skin whose severity may depend on external factors already mentioned. Included in this skin category are senile skin (characterized by a general decrease in cutaneous metabolism with age), fragile skin (very sensitive to external factors and often accompanied by erythema and rosacea) and vulvar xerosis (d probable genetic origin and manifesting itself primarily on the face, limbs and back of the hands).
- compositions and method according to the invention thus prove to be particularly effective in preventing and / or treating sensitive and / or dry skin and more particularly so-called reactive, irritable and / or intolerant skin, dry skin and / or dry constitutional skin.
- compositions according to the invention involve at least one microorganism belonging to the species Lactobacillus paracasei or case ⁇ , in particular a microorganism belonging to the species Lactobacillus paracasei, and in particular a microorganism belonging to the species Lactobacillus paracase1 STl 1 NCC 2461.
- Bifidobacterium Longum it may more particularly be selected from Bifidobacterium Longum NCC 490 (CNCM 1-2170). Another strain of Bifidobacterium longum is marketed under the name Bb 536 by MORINAGA.
- Bb 536 Another strain of Bifidobacterium longum is marketed under the name Bb 536 by MORINAGA.
- the microorganism belonging to the species Bifidobacterium lactis it may more particularly be the species Bifidobacterium lactis NCC 2818 (CNCM 1-3446).
- the use and the compositions according to the invention implement at least the microorganism Lactobacillus paracasei STI 1, NCC 2461 (CNCM 1-2116) one of its fractions or one of its metabolites and at least one Bifidobacterium Longum NCC 490 microorganism (CNCM 1-2170), one of its fractions or one of its metabolites.
- the use and the compositions according to the invention implement the microorganism Lactobacillus paracasei STl 1 NCC 2461 (CNCM 1-2116), one of its fractions or one of its metabolites, and at least one microorganism Bifidobacterium lactis NCC 2818 (CNCM 1-3446), one of its fractions or one of its metabolites.
- the term "metabolite” refers to any substance resulting from the metabolism of the microorganisms considered according to the invention and also having an efficacy for the treatment of sensitive and / or dry skin.
- the term “fraction” refers more particularly to a fragment of said microorganism having an efficacy for the treatment of dry and / or sensitive skin by analogy with said whole microorganism.
- Each of the microorganisms and / or metabolites and / or corresponding fractions may be formulated in a suitable carrier in an amount of at least 10 3 PDUs / g, especially at rate of 10 5 to 10 15 PDUs / g and more particularly at a rate of 10 7 to 10 12 cfu / g.
- Lactobacillus paracasei or Casei / Bifidobacterium longum or Lactobacillus paracasei or Casei / Bifidobacterium lactis which varies from 0.5 to 1.5, in particular from 0.7 to 1. , 2 and more particularly of the order of 1.
- compositions according to the invention implement at least said microorganisms in equivalent amounts and more particularly at 10 10 cfu respectively.
- microorganisms can be formulated in the form of powders, that is to say in a dry form, or in the form of suspensions or solutions.
- these microorganisms can be formulated in an encapsulated form so as to significantly improve their survival time.
- the presence of a capsule may in particular delay or prevent degradation of the microorganism in the gastrointestinal tract.
- These microorganisms may further contain being associated with at least one microorganism belonging to a distinct species, including a species of probiotic type and / or one of its fractions and / or one of its metabolites.
- probiotic microorganism means a living microorganism which, when consumed in an adequate quantity, has a positive effect on the health of its host.
- microorganisms that are suitable for the invention may be chosen in particular from ascomycetes such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora,
- Saccharomyces cereviseae Torulaspora, Schizosaccharamycespom.be, Candida and Pichia.
- probiotic microorganisms are examples of probiotic microorganisms.
- Bifidobacterium bifidum Bifidobacterium infantis, Lactobacillus acidophilus,
- Lactobacillus alimentarius Lactobacillus curvatus, Lactobacillus delbruckii subsp. Lactis, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus sake, Lactococcus lactis, Streptococcus thermophilus, Staphylococcus carnosus, and Staphylococcus xylosus and mixtures thereof.
- lactic acid bacteria such as Lactobacillus and / or Bifidobacterium.
- these lactic acid bacteria Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Bifidobacterium bifidum, Short Bifidobacterium, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum, and mixtures thereof, may be mentioned in particular.
- a strain of Bifidobacterium lactis can be obtained from Hansen (Chr.
- Lactobacillus johnsonii and Bifidobacterium adolescentis are Lactobacillus johnsonii and Bifidobacterium adolescentis, respectively deposited according to the Budapest Treaty with the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris cedex 15) under the following designations CNCM 1-1225 and CNCM 1 -2168 and mixtures thereof.
- the use or a composition according to the invention can also implement at least one microorganism belonging to the species Bifidobacterium lactis.
- the use or a composition according to the invention can also implement at least one microorganism belonging to the species Bifidobacterium longum.
- microorganisms and / or their fractions and / or metabolites may be formulated in a suitable carrier in an amount of at least 10 3 PDUs / g, particularly at doses ranging October 5 to October 15 cfu / g, more particularly from 10 7 to 10 12 cfu / g of support.
- suitable carrier in an amount of at least 10 3 PDUs / g, particularly at doses ranging October 5 to October 15 cfu / g, more particularly from 10 7 to 10 12 cfu / g of support.
- the formulations previously described for the microorganisms belonging to the species constituting the associations more particularly considered according to the invention namely Lactobacillus paracasei or casei, Bifidobacterium Longum and / or Bifidobacteriul lactis can of course be considered for the aforementioned microorganisms.
- compositions according to the invention and in particular those intended to be administered orally can include for living microorganisms October 3 to October 15 cfu / g, in particular October 5 to October 15 cfu / g and more particularly from 10 7 to 10 12 cfu / g of microorganisms per gram of carrier or equivalent doses calculated for inactive or dead microorganisms or for microorganism fractions or metabolites produced.
- the compositions for topical application according to the invention generally comprise from 10 3 to 10 12 cfu / g, in particular from 10 5 to 10 10 cfu / g and more particularly from 10 7 to 10 9 cfu / g of microorganisms, in particular probiotics.
- the contents of metabolites in the compositions correspond substantially to the contents that may be produced by October 3 to October 15 cfu, particularly October 5 to October 15 cfu, more particularly October 7 to October 12 cfu of live microorganisms per gram of support.
- the concentration of each microorganism and / or fraction and / or corresponding metabolite may be adjusted so as to correspond to doses (expressed in microorganism equivalent) ranging from 5 ⁇ 10 5 to 10 13 cfu / day and in particular 10 8 to 10 11 cfu / day.
- the microorganism (s) may be included in the composition according to the invention in a living, semi-active or inactivated, dead form.
- microorganism (s), metabolite (s) or fraction (s) can also be introduced in the form of a freeze-dried powder, a culture supernatant and / or the where appropriate in a concentrated form.
- compositions it may be advantageous to use these microorganisms in inactivated or even dead form.
- compositions according to the invention may furthermore employ one or more divalent mineral cation (s).
- the divalent mineral cations can be used in different forms.
- the divalent mineral cation may thus be in the form of an inorganic or organic salt, anhydrous or hydrated or a chelated complex.
- salts can be, for example, carbonates, bicarbonates, sulphates, glycerophosphates, chlorides, nitrates, acetates, hydroxides, oxides, salts of ⁇ -hydroxy acids (citrates, tartrates, lactates, malates) or of fruit acids, or salts of amino acids (aspartate, arginate, fumarate) or salts of fatty acids (palmitate, oleate, caseinate, behenate).
- the divalent mineral cation is chosen from manganese, copper and / or zinc.
- the divalent mineral cation is an alkaline earth metal.
- alkaline earth metal used in the invention mention may be made of barium, calcium, magnesium, strontium and / or beryllium.
- the divalent inorganic cation and in particular alkaline earth metal is used in the present invention in salt form.
- the salt may be chosen from calcium nitrate, strontium nitrate, magnesium gluconate, calcium lactate, strontium gluconate, magnesium lactate, calcium chloride, strontium chloride, magnesium chloride, calcium carbonate, strontium sulfate, magnesium sulfate, calcium glycerophosphate, citrate calcium, magnesium citrate, strontium acetate, magnesium acetate and mixtures thereof.
- At least one divalent mineral cation chosen from the salts of citrate, chloride, gluconate, sulfate, lactate and / or acetate, strontium, calcium and / or magnesium and their mixtures is used.
- the divalent mineral cation may also be used in the form of a chelated complex, in particular with crystallized or ionized proteins.
- the divalent inorganic cation may also be in a specific form stored by a microorganism, for example of yeast type, like selenium yeasts.
- the cations can be introduced as such into the compositions according to the invention or by means of a compound or mixture of compound (s) known to contain at least one of these cations in a high concentration.
- a source of metal salts an extract of plants or yeasts enriched in cations can be used.
- the calcium may for example be introduced via a milk extract.
- the divalent mineral cation content used in the compositions according to the invention depends of course on the form of the cation in question and can be determined by simple routine experiments. These daily doses can in particular range from 100 ⁇ g to 5 g, more particularly from 1 mg to 2 g, or even from 10 mg to 1.3 g.
- the divalent mineral cation concentration may be adjusted to correspond to doses ranging from 1 to 3000 mg / day and in particular from 10 to 2000 mg / day.
- compositions according to the invention are generally administered topically or orally.
- the compositions according to the invention may be in any of the galenical forms normally used according to the route of use.
- the support may be of a different nature depending on the type of composition considered.
- suitable food or pharmaceutical carriers are milk, yoghurt, cheese, fermented milk, fermented milk products, ice cream, fermented cereal products, milk-based powders, formulas for children and infants, especially pet food, tablets or tablets, suspensions of liquid bacteria, oral supplements in dry form and oral supplements in liquid form.
- the composition according to the invention may be a food composition for human consumption.
- This may include, in particular, whole nutritional foods, beverages, mineral waters, soups, dietary supplements and substitute foods, nutritional bars, confectionery, milk-based products or fermented milk, yogurt, milk-based powders, enteral nutrition products, children's and / or infants' compositions, cereal-based products or fermented cereal products, ice cream, chocolate, coffee, "culinary" products such as mayonnaise, tomato puree or salad dressings.
- the composition according to the invention may also be intended for animals.
- cosmetic products they may be aqueous, hydroalcoholic or oily solutions, dispersions of the type of solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type. , suspensions or emulsions, of the cream type, aqueous or anhydrous gel, microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and / or nonionic type.
- oral compositions and in particular dietary supplements are possible. Their formulation is carried out by the usual methods for producing dragees, capsules, gels, emulsions, tablets, capsules or solutions.
- the active ingredient (s) according to the invention can be incorporated into all other forms of food supplements or fortified foods, for example food bars, or compacted powders or not.
- the powders can be diluted with water, in soda, dairy products or soy derivatives, or incorporated into food bars.
- the active agents according to the invention can be formulated with the excipients and components customary for such oral compositions or food supplements, namely in particular fatty and / or aqueous components, humectants, thickeners, preservatives, texture, flavor and / or coating agents, antioxidants, preservatives and dyes common in the field of food.
- the formulating agents and excipients for oral composition, and especially for food supplements, are known in this field and are not the subject of a detailed description here.
- oral compositions according to the invention may contain several other active ingredients.
- active agents that may be mentioned are vitamins B3, B5, B6, B8, C, E, or PP, carotenoids, curcuminoids and niacin.
- an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids such as as catechins, hesperidin, proanthocyanidins and anthocyanins.
- a carotenoid chosen from ⁇ -carotene, lycopene, astaxanthin, zeaxanthin and lutein, flavonoids such as as catechins, hesperidin, proanthocyanidins and anthocyanins.
- the composition advantageously comprises at least one prebiotic or a mixture of prebiotics.
- these prebiotics may be chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gums, of the acacia type for example, or one of their mixtures.
- the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructo-oligosaccharide and inulin.
- the cosmetic and / or dermatological compositions may especially be in the form of aqueous, hydroalcoholic or oily solutions, dispersions of the type of solutions or dispersions of the lotion or serum type, of emulsions of liquid consistency. or semi-liquid of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream type , aqueous or anhydrous gel, or microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and / or nonionic type.
- compositions are prepared according to the usual methods. These compositions may in particular constitute creams for cleaning, protection, treatment or care for the face, for the hands, for the feet, for large anatomical folds or for the body, (for example, day creams, night creams). , make-up removing creams, foundation creams, sunscreen creams), make-up products such as fluid foundations, make-up removing milks, protective or skincare body milks, after-sun milks, lotions, gels or skin care foams, such as cleaning or disinfecting lotions, sunscreen lotions, artificial tanning lotions, bathing compositions, deodorant compositions containing a bactericidal agent, gels or lotions after shaving, depilatory creams, or insect bites.
- creams for cleaning, protection, treatment or care for the face, for the hands, for the feet, for large anatomical folds or for the body, (for example, day creams, night creams).
- make-up removing creams, foundation creams, sunscreen creams make-up products such
- compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars. They may also be used for hair in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions, foams or in the form of aerosol compositions also containing a propellant under pressure.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the oils, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics and / or dermatological field.
- the emulsifier and the coemulsifier may be present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- the fatty phase may represent more than 90% of the total weight of the composition.
- the cosmetic and / or dermatological composition of the invention may also contain adjuvants customary in the pharmaceutical and / or dermatological cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants solvents, perfumes, fillers, filters, bactericides, odor absorbers and dyestuffs.
- adjuvants customary in the pharmaceutical and / or dermatological cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants solvents, perfumes, fillers, filters, bactericides, odor absorbers and dyestuffs.
- the amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase and / or into the aqueous phase.
- Fats which can be used in the invention include mineral oils such as, for example, hydrogenated polyisobutene and liquid petroleum jelly, vegetable oils such as, for example, a liquid fraction of shea butter, sunflower oil and almonds. apricot, animal oils such as perhydrosqualene, synthetic oils including Purcellin oil, isopropyl myristate and ethyl hexyl palmitate, and fluorinated oils such as perfluoropolyethers. It is also possible to use fatty alcohols, fatty acids such as stearic acid and, for example, waxes such as paraffin, carnauba and beeswax. It is also possible to use silicone compounds such as silicone oils and, for example, cyclomethicone and dimethicone, waxes, resins and silicone gums. These compounds can be functionalized or not.
- mineral oils such as, for example, hydrogenated polyisobutene and liquid petroleum jelly
- vegetable oils such as, for example, a liquid fraction of shea
- emulsifiers used in the invention there may be mentioned for example glycerol stearate, polysorbate 60, the mixture of cetylstearyl alcohol / oxyethylenated cetylstearyl alcohol with 33 moles of ethylene oxide sold under the name Sinnowax AO ® by the company Henkel , the mixture of PEG-6 / PEG-32 / glycol stearate sold under the name Tefose ® 63 by the company Gattefosse, PPG-3 myristyl ether, silicone emulsifiers such as cetyl dimethicone copolyol and the mono- or sorbitan tristearate, PEG-40 stearate, oxyethylenated sorbitan monostearate (20OE).
- solvents that can be used in the invention mention may be made of lower alcohols, in particular ethanol and isopropanol, and propylene glycol.
- hydrophilic gelling agents such as carbomer, acrylic copolymers such as copolymers of acrylates / alkyl acrylates, polyacrylamides and in particular the polyacrylamide mixture, C13-14-Isoparaffin and Laureth-7 sold under the name Sepigel 305 ® by the company SEPPIC, polysaccharides such as cellulose derivatives such as hydroxyalkylcelluloses, and in particular hydroxypropylcellulose and hydroxyethylcellulose, natural gums such as guar, locust bean and xanthan and clays.
- carboxylic polymers such as carbomer, acrylic copolymers such as copolymers of acrylates / alkyl acrylates, polyacrylamides and in particular the polyacrylamide mixture, C13-14-Isoparaffin and Laureth-7 sold under the name Sepigel 305 ® by the company SEPPIC
- polysaccharides such as cellulose derivatives such as hydroxyalkylcelluloses, and in particular hydroxypropyl
- lipophilic gelling agents mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, or else ethylcellulose and polyethylene.
- hydrophilic active agents it is possible to use proteins or protein hydrolysates, amino acids, and especially C 2 -C 10 polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, Fallantoin, sugars and the like. sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as those of Aloe Vera.
- retinol vitamin A
- tocopherol vitamin E
- ceramides essential oils
- the active agents according to the invention may be combined with active agents intended in particular for the prevention and / or treatment of cutaneous affections.
- the composition of the invention may advantageously contain a thermal and / or mineral water, in particular chosen from Vittel water, the waters of the Vichy basin and Roche Posay water.
- the cosmetic treatment method of the invention may be implemented in particular by applying the cosmetic and / or dermatological compositions as defined above, according to the usual technique of use of these compositions. For example: applications of creams, gels, serums, lotions, cleansing milks or after-sun compositions on the skin or on dry hair, application of a hair lotion on wet hair, shampoos, or still application of toothpaste on the gums.
- the cosmetic process according to the invention can be implemented by topical administration or by daily oral administration, for example, of the combination according to the invention which can be, for example, formulated in the form of capsules, gels, lotions, dragees, emulsions, tablets, capsules or drinkable ampoules, in an appropriate quantity and number, according to their form, so that the active ingredients are administered at a rate of 5 ⁇ 10 5 to 10 13 cfu per day, in particular 10 6 to 10 11 cfu per day, in microorganisms or equivalent doses of partially inactivated or dead microorganisms or fractions of microorganisms or metabolites produced.
- the administration is repeated until the divalent mineral cation is administered at doses of the order of 1 to 3000 mg per day, and in particular of 10 to 2000 mg per day.
- the method according to the invention may comprise a single administration.
- the administration is repeated for example 2 to 3 times daily for a day or more and generally for an extended period of at least 4 weeks, or even 4 to 15 weeks, with one or more periods of interruption if necessary.
- percentages are percentages by weight and ranges of values in the form "between ... and " include the specified lower and upper bounds.
- the ingredients are mixed, before they are shaped, in the order and under conditions easily determined by those skilled in the art.
- compositions for the oral route are provided.
- Example 3 capsule
- One to three of these capsules can be taken daily.
- This type of dragee can be taken 1 to 3 times a day.
- This type of dragee can be taken 1 to 3 times a day.
- Example 8 capsule
- One to three of these capsules can be taken daily.
- This type of dragee can be taken 1 to 3 times a day.
- This type of dragee can be taken 1 to 3 times a day.
- composition for the topical route examples include:
- Example 11 Lotion for the face of sensitive skin
- Example 12 milk for the care of the face of dry and sensitive skin
- Example 13 gel for the care of the face of sensitive skin
- Example 14 milk for the care of the face of dry and sensitive skin
- Example 16 milk for the care of the face of dry and sensitive skin
- Example 17 gel for the care of the face of sensitive skin Strontium nitrate 4.00 Lactobacillus paracasei powder STl 1 NCC 2461
- Powder Bifidobacterium lactis NCC 2818 (CNCM 1-3446) 5.00 Hydroxypropylcellulose (Klucel H ® sold by the company Hercules) 1.00
- Example 18 milk for the care of the face of dry and sensitive skin
- Glycerol stearate 1.00 Cetylstearyl alcohol / oxyethylenated cetylstearyl alcohol with 3 moles EO (AO ® Sinnowax sold by the company Henkel) 3.00 Cetyl alcohol 1.00 Dimethicone (DC 200 Fluid ® sold by the company Dow Corning) 1 00
- the treatment consists of administering a single treatment unit daily and orally for a period of eight weeks.
- the oral composition according to the invention of the example was tested in terms of cutaneous sensitivity in the subjects considered for the study (assessment of cutaneous sensitivity by a lactic acid test or stinging test).
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005291098A AU2005291098B2 (en) | 2004-10-04 | 2005-10-03 | Cosmetic and/or dermatological composition for sensitive skins |
CN2005800371890A CN101090706B (zh) | 2004-10-04 | 2005-10-03 | 用于敏感性皮肤的化妆品和/或皮肤用组合物 |
JP2007534067A JP5112069B2 (ja) | 2004-10-04 | 2005-10-03 | 敏感肌のための化粧品及び/または皮膚科組成物 |
BRPI0516437-0A BRPI0516437A (pt) | 2004-10-04 | 2005-10-03 | utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral |
MX2007004135A MX2007004135A (es) | 2004-10-04 | 2005-10-03 | Composicion cosmetica y/o dermatologica para pieles sensibles. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0452258A FR2876029B1 (fr) | 2004-10-04 | 2004-10-04 | Composition cosmetique et/ou dermatologique pour peaux sensibles. |
FR0452258 | 2004-10-04 | ||
US63453904P | 2004-12-10 | 2004-12-10 | |
US60/634,539 | 2004-12-10 | ||
EP05012301.7 | 2005-06-08 | ||
EP05012301A EP1731137A1 (fr) | 2005-06-08 | 2005-06-08 | Composition cosmétique ou dermatologique pour peaux sèches et/ou sensibles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006037922A1 true WO2006037922A1 (fr) | 2006-04-13 |
Family
ID=35725050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/050807 WO2006037922A1 (fr) | 2004-10-04 | 2005-10-03 | Composition cosmetique et/ou dermatologique pour peaux sensibles |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060171936A1 (fr) |
JP (1) | JP5112069B2 (fr) |
AU (1) | AU2005291098B2 (fr) |
BR (1) | BRPI0516437A (fr) |
MX (1) | MX2007004135A (fr) |
WO (1) | WO2006037922A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008179601A (ja) * | 2006-12-28 | 2008-08-07 | Suntory Ltd | ラクトバチルス属菌を含む美容組成物 |
FR2912916A1 (fr) * | 2007-02-26 | 2008-08-29 | Oreal | Composition cosmetique ou dermatologique comprenant un milieu de culture cellulaire |
FR2912917A1 (fr) * | 2007-02-26 | 2008-08-29 | Oreal | Milieu conditionne et ses utilisations |
FR2920307A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation cosmetique de microorganismes. |
FR2920300A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation d'une association hesperidine et microorganisme pour agir sur la fonction barriere de la peau. |
FR2920301A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation d'une association hesperidine et microogansime pour le traitement de la secheresse des matieres keratiniques. |
WO2009031106A2 (fr) * | 2007-09-04 | 2009-03-12 | L'oreal | Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau |
JP2009108031A (ja) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | ビフィドバクテリウム種の溶解産物を敏感肌の処置のために用いる方法 |
JP2009108030A (ja) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | ビフィドバクテリウム種溶解産物を乾燥の処置のために化粧的に用いる方法 |
WO2010013179A1 (fr) * | 2008-07-29 | 2010-02-04 | L'oreal | Utilisation cosmétique de microorganismes pour le traitement d'une peau grasse |
EP2206493A1 (fr) | 2009-01-12 | 2010-07-14 | L'oreal | Association cosmétique d'un microorganisme et d'un dérivé phytosphingosine |
FR2942720A1 (fr) * | 2009-03-03 | 2010-09-10 | Oreal | Utilisation cosmetique d'hesperidine. |
JP2011518873A (ja) * | 2008-04-29 | 2011-06-30 | ロレアル | 微生物の凍結乾燥物及び12以上のhlbを持つ界面活性剤を主成分とするその場で調製できるケア製品 |
US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
WO2014096641A1 (fr) | 2012-12-17 | 2014-06-26 | Laboratoires Urgo | Méthode pour prévenir et/ou traiter les infections, colonisations ou maladies liées à staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans et/ou malassezia furfur |
US9176144B2 (en) | 2006-11-17 | 2015-11-03 | L'oreal | Cosmetic use of a protein belonging to the ribonuclease family |
US9782611B2 (en) | 2008-10-28 | 2017-10-10 | L'oreal | Treatment of greasy skin with a bacterial lystate |
EP2149368B1 (fr) * | 2008-07-29 | 2018-05-30 | L'Oréal | Utilisation en cosmétique et dermatologiques de microorganismes probiotiques de Lactobacillus paracasei pour le traitement de troubles du cuir chevelu graisseux |
CN114717128A (zh) * | 2021-04-18 | 2022-07-08 | 青岛蔚蓝生物股份有限公司 | 一株具有改善衰老皮肤和增强毛发健康作用的罗伊氏乳杆菌及其应用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2889057B1 (fr) * | 2005-08-01 | 2008-07-18 | Oreal | Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches |
US20080107699A1 (en) * | 2006-10-25 | 2008-05-08 | Mark Spigelman | Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor |
US9125768B2 (en) * | 2006-11-17 | 2015-09-08 | Sca Hygiene Products Ab | Hygiene tissue comprising a microbe-inhibiting composition |
WO2008060200A1 (fr) | 2006-11-17 | 2008-05-22 | Sca Hygiene Products Ab | Article d'hygiène contenant une composition anti-microbienne |
US8222020B2 (en) * | 2006-11-17 | 2012-07-17 | Sca Hygiene Products Ab | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 |
FR2915388B1 (fr) * | 2007-04-27 | 2010-12-24 | Oreal | Film hydrosoluble cosmetique |
WO2008154141A2 (fr) * | 2007-05-22 | 2008-12-18 | Prelief Inc. | Compositions et procédés pour prévenir, minimiser et soigner une irritation et une lésion cutanée |
FR2919501B1 (fr) * | 2007-08-02 | 2010-12-31 | Oreal | Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees |
PT2612562E (pt) * | 2008-03-28 | 2015-04-22 | Nestec Sa | Probióticos para utilização em fêmeas de mamíferos gestantes para reforçar a imunidade da sua descendência |
US8128949B2 (en) | 2008-04-14 | 2012-03-06 | John Mosher | Kit for insect bites |
JP5254682B2 (ja) * | 2008-06-27 | 2013-08-07 | 株式会社ヤクルト本社 | 経口摂取用皮膚性状改善剤 |
FR2937536B1 (fr) * | 2008-10-28 | 2016-07-01 | Oreal | Utilisation cosmetique d'un lysat de bifidobacterium species pour le traitement du cuir chevelu gras |
BRPI1012849A2 (pt) * | 2009-05-11 | 2018-06-19 | Nestec Sa | lactobacillus johnsonii la1 ncc533 (cncm i-1225) e distúrbios imunes |
EP2251020A1 (fr) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Traitement haute température de courte durée qui génère des préparations microbiennes avec des profils anti-inflammatoires |
JP2013507394A (ja) * | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
FR2953408B1 (fr) * | 2009-12-08 | 2013-02-08 | Oreal | Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau |
FR2953407B1 (fr) * | 2009-12-08 | 2013-06-14 | Oreal | Microorganismes probiotiques a titre d'actif contre les alterations du microrelief |
JP6446037B2 (ja) * | 2013-09-30 | 2018-12-26 | イーエルシー マネージメント エルエルシー | ウォータリーローションスキンケア組成物および方法 |
EP3359174A1 (fr) * | 2015-10-07 | 2018-08-15 | Galderma Research & Development | Composition contenant des bactéries d'acide lactique et son utilisation pour traiter la dermatite atopique |
WO2017063066A1 (fr) * | 2015-10-15 | 2017-04-20 | Natura Cosméticos S.A. | Composition cosmétique contenant des bactéries probiotiques |
CA3018866C (fr) | 2016-03-31 | 2024-03-26 | Gojo Industries, Inc. | Composition de desinfectant comprenant un principe actif probiotique/prebiotique |
WO2017173240A1 (fr) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Composition nettoyante stimulant les peptides antimicrobiens |
EP3272396A1 (fr) * | 2016-07-18 | 2018-01-24 | Bionou Research, S.L. | Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique |
CA3043748A1 (fr) | 2016-11-23 | 2018-05-31 | Gojo Industries, Inc. | Composition desinfectante comprenant une substance active probiotique/prebiotique |
TWI746955B (zh) * | 2018-04-25 | 2021-11-21 | 日商曾根農場股份有限公司 | 第i型過敏用組成物 |
RU2767400C2 (ru) * | 2018-07-05 | 2022-03-17 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Пробиотическая композиция для восстановления и поддержания сбалансированной микрофлоры кишечника у детей и младенцев и способ ее получения |
RU2729633C2 (ru) * | 2018-07-05 | 2020-08-11 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Биологически активная пищевая добавка для профилактики воспалительного заболевания кишечника и функциональных кишечных расстройств и способ ее получения |
AT17326U1 (de) * | 2021-03-29 | 2021-12-15 | Sanubiom Gmbh | Hautpflegezusammensetzung in Pulverform, aus dem ein Gel hergestellt wird |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737471A2 (fr) * | 1995-04-10 | 1996-10-16 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
WO2001045721A1 (fr) * | 1999-12-22 | 2001-06-28 | Societe Des Produits Nestle S.A. | Agent anti-adhesion de la flore pathogene de la peau |
WO2001097822A1 (fr) * | 2000-06-20 | 2001-12-27 | Oy Aboatech Ab | Probiotiques pour la prevention primaire de maladies atopiques |
WO2003070260A1 (fr) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | Composition photoprotectrice pour la peau a administrer oralement |
WO2003099037A1 (fr) * | 2002-05-24 | 2003-12-04 | Nestec S.A. | Probiotiques et tolerance orale |
WO2004052462A1 (fr) * | 2002-12-05 | 2004-06-24 | Danisco France | Composition comprenant des lactobacillus ou des bifidobacterium et son utilisation |
EP1609463A1 (fr) * | 2004-06-23 | 2005-12-28 | L'oreal | Procédé et compositions utiles pour prévenir et/ou traiter les peaux sensibles et/ou sèches |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3024318A1 (de) * | 1980-06-27 | 1982-01-28 | Chemisches Laboratorium Dr. Karl Richter GmbH, 1000 Berlin | Kosmetische mittel |
LU85544A1 (fr) * | 1984-09-19 | 1986-04-03 | Cird | Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique |
LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
JPH0687732B2 (ja) * | 1987-02-25 | 1994-11-09 | カルピス食品工業株式会社 | ビフイズス菌入り発酵乳の製造法 |
LU87109A1 (fr) * | 1988-01-20 | 1989-08-30 | Cird | Esters et thioesters aromatiques,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
AU639373B2 (en) * | 1990-10-22 | 1993-07-22 | Unilever Plc | Cosmetic composition |
US5110593A (en) * | 1990-11-13 | 1992-05-05 | Benford M Sue | Irradication and treatment of diaper dermatitis and related skin disorders |
US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
JPH0517363A (ja) * | 1991-07-11 | 1993-01-26 | Yakult Honsha Co Ltd | 抗炎症剤及びそれを含有する化粧料 |
IT1253265B (it) * | 1991-11-25 | 1995-07-14 | Rotta Research Lab | Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo. |
JP3347381B2 (ja) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | ペットフード |
US5733568A (en) * | 1993-12-03 | 1998-03-31 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5656268A (en) * | 1995-04-21 | 1997-08-12 | Sorodsky; Michael | Biological product |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
US5882665A (en) * | 1997-11-18 | 1999-03-16 | Elizabeth Arden Co., Division Of Conopco, Inc. | Phytosphingosine salicylates in cosmetic compositions |
SE510813C2 (sv) * | 1997-12-08 | 1999-06-28 | Arla Ekonomisk Foerening | Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen |
DK0931543T3 (da) * | 1997-12-19 | 2002-06-17 | Merck Patent Gmbh | Flerlagstabletter indeholdende probiotiske mikroorganismer såsom lactobacilli eller bifidobakterier |
US6492488B1 (en) * | 1998-08-02 | 2002-12-10 | Pmd Holdings Corp. | Controlled release polyacrylic acid granules and a process for preparing the same |
EP1120108B1 (fr) * | 1998-10-09 | 2006-08-02 | Kabushiki Kaisha Yakult Honsha | Preparations dermatologiques a usage externe |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
GB9828379D0 (en) * | 1998-12-22 | 1999-02-17 | Unilever Plc | Skin care composition |
KR100324441B1 (ko) * | 1999-02-08 | 2002-02-27 | 이은선 | 위염, 위궤양, 십이지장궤양 예방을 위한 식품 |
GB9918023D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
EP1322318B1 (fr) * | 2000-10-06 | 2010-12-08 | Nestec S.A. | Utilisation de bacteries lactiques probiotiques afin de prévenir les reactions inflammatoires ou allergiques ou l'immunosuppression causée par des radiations ultraviolettes sur la peau |
BR0116679A (pt) * | 2000-12-19 | 2004-01-13 | Yakult Honsha Kk | Preparações para a pele para aplicação externa e processo para a fabricação das mesmas |
WO2002065840A2 (fr) * | 2001-02-19 | 2002-08-29 | Societe Des Produits Nestle S.A. | Produit consommable contenant des probiotiques |
US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
GB0119583D0 (en) * | 2001-08-10 | 2001-10-03 | Unilever Plc | Cosmetic composition and method of treating skin |
CA2477144C (fr) * | 2002-02-21 | 2011-06-14 | Societe Des Produits Nestle S.A. | Composition administrable par voie orale pour la photoprotection de la peau |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
KR20050094403A (ko) * | 2002-12-13 | 2005-09-27 | 로레알 | 경구 투여로 피부의 피지 기능을 자극하기 위한 조성물제조에서의 카페인 제거 커피 원두 추출물의 용도 |
CN100553632C (zh) * | 2003-12-18 | 2009-10-28 | 雀巢技术公司 | 用于改善皮肤、头发和皮毛健康的包含黄烷酮的组合物 |
JP2008503563A (ja) * | 2004-06-23 | 2008-02-07 | ロレアル | 敏感及び/又は乾燥肌の予防及び/又は処置に有用な方法及び組成物 |
US7651860B2 (en) * | 2004-12-17 | 2010-01-26 | Enviro Tech Chemical Services, Inc. | Method of analyzing low levels of peroxyacetic acid in water |
FR2889057B1 (fr) * | 2005-08-01 | 2008-07-18 | Oreal | Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches |
US20070154500A1 (en) * | 2005-12-21 | 2007-07-05 | L'oreal | Composition containing concave particles and a dispersant, processes and uses |
US20080159970A1 (en) * | 2006-12-20 | 2008-07-03 | L'oreal | Kit comprising silicone compounds and a cosmetic and/or dermatological active agent |
FR2912917B1 (fr) * | 2007-02-26 | 2012-05-18 | Oreal | Milieu conditionne et ses utilisations |
FR2917969B1 (fr) * | 2007-06-26 | 2010-12-10 | Oreal | Utilisation cosmetique d'un derive d'acide imido-percarboxylique a titre d'agent desquamant |
MX2010002247A (es) * | 2007-09-04 | 2010-05-17 | Oreal | Uso de una combinacion de hesperidina y de un microorganismo para influir en la funcion de barrera de la piel. |
EP2149368B1 (fr) * | 2008-07-29 | 2018-05-30 | L'Oréal | Utilisation en cosmétique et dermatologiques de microorganismes probiotiques de Lactobacillus paracasei pour le traitement de troubles du cuir chevelu graisseux |
FR2937547B1 (fr) * | 2008-10-28 | 2012-11-09 | Oreal | Utilisation d'un lysat de microorganisme pour le traitement des peaux grasses |
FR2953408B1 (fr) * | 2009-12-08 | 2013-02-08 | Oreal | Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau |
-
2005
- 2005-10-03 MX MX2007004135A patent/MX2007004135A/es active IP Right Grant
- 2005-10-03 JP JP2007534067A patent/JP5112069B2/ja not_active Expired - Fee Related
- 2005-10-03 BR BRPI0516437-0A patent/BRPI0516437A/pt not_active Application Discontinuation
- 2005-10-03 WO PCT/FR2005/050807 patent/WO2006037922A1/fr active Application Filing
- 2005-10-03 AU AU2005291098A patent/AU2005291098B2/en not_active Ceased
- 2005-10-04 US US11/241,964 patent/US20060171936A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737471A2 (fr) * | 1995-04-10 | 1996-10-16 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
WO2001045721A1 (fr) * | 1999-12-22 | 2001-06-28 | Societe Des Produits Nestle S.A. | Agent anti-adhesion de la flore pathogene de la peau |
WO2001097822A1 (fr) * | 2000-06-20 | 2001-12-27 | Oy Aboatech Ab | Probiotiques pour la prevention primaire de maladies atopiques |
WO2003070260A1 (fr) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | Composition photoprotectrice pour la peau a administrer oralement |
WO2003099037A1 (fr) * | 2002-05-24 | 2003-12-04 | Nestec S.A. | Probiotiques et tolerance orale |
WO2004052462A1 (fr) * | 2002-12-05 | 2004-06-24 | Danisco France | Composition comprenant des lactobacillus ou des bifidobacterium et son utilisation |
EP1609463A1 (fr) * | 2004-06-23 | 2005-12-28 | L'oreal | Procédé et compositions utiles pour prévenir et/ou traiter les peaux sensibles et/ou sèches |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176144B2 (en) | 2006-11-17 | 2015-11-03 | L'oreal | Cosmetic use of a protein belonging to the ribonuclease family |
JP2008179601A (ja) * | 2006-12-28 | 2008-08-07 | Suntory Ltd | ラクトバチルス属菌を含む美容組成物 |
FR2912916A1 (fr) * | 2007-02-26 | 2008-08-29 | Oreal | Composition cosmetique ou dermatologique comprenant un milieu de culture cellulaire |
FR2912917A1 (fr) * | 2007-02-26 | 2008-08-29 | Oreal | Milieu conditionne et ses utilisations |
EP1974718A1 (fr) * | 2007-02-26 | 2008-10-01 | L'Oreal | Composition cosmétique ou dermatologique comprenant un milieu de culture cellulaire |
EP1974719A1 (fr) * | 2007-02-26 | 2008-10-01 | L'Oreal | Milieu conditionné et ses utilisations |
CN103462876A (zh) * | 2007-02-26 | 2013-12-25 | 莱雅公司 | 含有一种细胞培养基的美容品或皮肤药用组合物 |
CN101254164B (zh) * | 2007-02-26 | 2013-10-23 | 莱雅公司 | 含有一种细胞培养基的美容品或皮肤药用组合物 |
US8101167B2 (en) | 2007-02-26 | 2012-01-24 | L'oreal | Conditioned medium and uses thereof |
EP2082731A1 (fr) | 2007-09-04 | 2009-07-29 | L'oreal | Utilisation d'une association d'hespéridine et d'un microorganisme pour agir sur la fonction barrière de la peau |
US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
JP2009108030A (ja) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | ビフィドバクテリウム種溶解産物を乾燥の処置のために化粧的に用いる方法 |
FR2920307A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation cosmetique de microorganismes. |
WO2009031106A3 (fr) * | 2007-09-04 | 2009-08-06 | Oreal | Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau |
WO2009031099A3 (fr) * | 2007-09-04 | 2009-11-05 | L'oreal | Utilisation sous forme cosmétique de micro-organismes |
FR2920300A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation d'une association hesperidine et microorganisme pour agir sur la fonction barriere de la peau. |
WO2009031106A2 (fr) * | 2007-09-04 | 2009-03-12 | L'oreal | Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau |
US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
JP2009108031A (ja) * | 2007-09-04 | 2009-05-21 | L'oreal Sa | ビフィドバクテリウム種の溶解産物を敏感肌の処置のために用いる方法 |
FR2920301A1 (fr) * | 2007-09-04 | 2009-03-06 | Oreal | Utilisation d'une association hesperidine et microogansime pour le traitement de la secheresse des matieres keratiniques. |
WO2009031099A2 (fr) * | 2007-09-04 | 2009-03-12 | L'oreal | Utilisation sous forme cosmétique de micro-organismes |
JP2011518873A (ja) * | 2008-04-29 | 2011-06-30 | ロレアル | 微生物の凍結乾燥物及び12以上のhlbを持つ界面活性剤を主成分とするその場で調製できるケア製品 |
EP2149368B1 (fr) * | 2008-07-29 | 2018-05-30 | L'Oréal | Utilisation en cosmétique et dermatologiques de microorganismes probiotiques de Lactobacillus paracasei pour le traitement de troubles du cuir chevelu graisseux |
WO2010013179A1 (fr) * | 2008-07-29 | 2010-02-04 | L'oreal | Utilisation cosmétique de microorganismes pour le traitement d'une peau grasse |
US8951775B2 (en) | 2008-07-29 | 2015-02-10 | L'oreal | Cosmetic use of microorganisms for the treatment of oily skin |
US9782611B2 (en) | 2008-10-28 | 2017-10-10 | L'oreal | Treatment of greasy skin with a bacterial lystate |
FR2938437A1 (fr) * | 2008-11-19 | 2010-05-21 | Oreal | Utilisation cosmetique de microorganisme pour le traitement des peaux grasses |
US8709454B2 (en) | 2009-01-12 | 2014-04-29 | L'oreal | Combination of a microorganism and a phytosphingosine derivative, composition, methods of use |
EP2206493A1 (fr) | 2009-01-12 | 2010-07-14 | L'oreal | Association cosmétique d'un microorganisme et d'un dérivé phytosphingosine |
FR2942720A1 (fr) * | 2009-03-03 | 2010-09-10 | Oreal | Utilisation cosmetique d'hesperidine. |
US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
WO2014096641A1 (fr) | 2012-12-17 | 2014-06-26 | Laboratoires Urgo | Méthode pour prévenir et/ou traiter les infections, colonisations ou maladies liées à staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans et/ou malassezia furfur |
CN114717128A (zh) * | 2021-04-18 | 2022-07-08 | 青岛蔚蓝生物股份有限公司 | 一株具有改善衰老皮肤和增强毛发健康作用的罗伊氏乳杆菌及其应用 |
WO2022222259A1 (fr) * | 2021-04-18 | 2022-10-27 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri ayant des effets anti-âge et d'amélioration de la santé des cheveux améliorés, et son application |
CN114717128B (zh) * | 2021-04-18 | 2023-11-17 | 青岛蔚蓝生物股份有限公司 | 一株具有改善衰老皮肤和增强毛发健康作用的罗伊氏乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2005291098A1 (en) | 2006-04-13 |
US20060171936A1 (en) | 2006-08-03 |
MX2007004135A (es) | 2007-06-15 |
BRPI0516437A (pt) | 2008-09-02 |
JP5112069B2 (ja) | 2013-01-09 |
AU2005291098B2 (en) | 2011-11-24 |
JP2008515792A (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1609463B1 (fr) | Procédé et compositions utiles pour prévenir et/ou traiter les peaux sensibles et/ou sèches | |
WO2006037922A1 (fr) | Composition cosmetique et/ou dermatologique pour peaux sensibles | |
EP2033628B1 (fr) | Utilisation cosmétique de lysat des éspèces de Bifidobacterium pour le traitement de la sécheresse cutanée | |
EP2033627B1 (fr) | Utilisation d'un lysat de Bifidobacterium species pour le traitement de peaux sensibles | |
AU2005257033B2 (en) | Method and compositions useful for preventing and/or treating sensitive and/or dry skin | |
AU2006274792B2 (en) | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin | |
EP2332520A1 (fr) | Microorganismes probiotiques à titre d'actif pour l'éclat du teint de la peau | |
EP1642570A1 (fr) | Composition cosmétique et/ou dermatologique pour peaux sensibles | |
EP2181702A1 (fr) | Utilisation cosmétique d'un lysat de Bifidobacterium species pour le traitement du cuir chevelu gras | |
EP2332521A1 (fr) | Microorganismes probiotiques à titre d'actif contre les altérations du microrelief de la peau | |
FR2959128A1 (fr) | Utilisation cosmetique d'un lysat de bifidobacterium species pour le traitement des odeurs corporelles | |
EP1731137A1 (fr) | Composition cosmétique ou dermatologique pour peaux sèches et/ou sensibles | |
WO2009141544A2 (fr) | Utilisation d'un extrait de baie, et plus particulierement de wolfberry, pour le traitement de la secheresse des matieres keratiniques | |
FR2876029A1 (fr) | Composition cosmetique et/ou dermatologique pour peaux sensibles. | |
EP1932510A1 (fr) | Utilisation d'au moins un acide gras monoinsaturé pour le traitement des peaux, muqueuses et cuirs chevelus fragiles | |
CA2522717C (fr) | Composition cosmetique et/ou dermatologique pour peaux sensibles | |
WO2008078050A2 (fr) | Utilisation d'au moins un acide gras mono-insature pour le traitement des peaux, muqueuses ou semi-muqueuses et cuirs chevelus fragiles | |
FR2938429A1 (fr) | Utilisation cosmetique de microorganisme(s) pour le traitement des desordres du cuir chevelu | |
FR2945944A1 (fr) | Procede cosmetique de traitement des etats pelliculaires comprenant l'administration d'un microorganisme probiotique et d'un actif antipelliculaire | |
FR2967065A1 (fr) | Utilisation d'extrait de grenade pour prevenir et/ou traiter les sensations dysesthesiques des peaux et/ou des cuirs chevelus intolerants et/ou irritables |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007534067 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/004135 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580037189.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005291098 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005291098 Country of ref document: AU Date of ref document: 20051003 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase | ||
ENP | Entry into the national phase |
Ref document number: PI0516437 Country of ref document: BR |